Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

sapanisertib (CB-228)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Calithera

Drug class:

mTORC1 inhibitor, mTORC2 inhibitor

Related drugs:

NFE2L2 mutation	Lung Non-Small Cell Squamous Cancer	NFE2L2 mutation	Lung Non-Small Cell Squamous Cancer	CB-228 Sensitive: B - Late Trials CB-228 Sensitive : B	CB-228 Sensitive: B - Late Trials CB-228 Sensitive : B
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	CB-228 Sensitive: C2 – Inclusion Criteria CB-228 Sensitive : C2	CB-228 Sensitive: C2 – Inclusion Criteria CB-228 Sensitive : C2
KEAP1 mutation	Lung Non-Small Cell Squamous Cancer	KEAP1 mutation	Lung Non-Small Cell Squamous Cancer	CB-228 Sensitive: C2 – Inclusion Criteria CB-228 Sensitive : C2	CB-228 Sensitive: C2 – Inclusion Criteria CB-228 Sensitive : C2
NFE2L2 mutation	Lung Cancer	NFE2L2 mutation	Lung Cancer	CB-228 Sensitive: C2 – Inclusion Criteria CB-228 Sensitive : C2	CB-228 Sensitive: C2 – Inclusion Criteria CB-228 Sensitive : C2
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	tamoxifen + CB-228 Sensitive: C3 – Early Trials tamoxifen + CB-228 Sensitive : C3	tamoxifen + CB-228 Sensitive: C3 – Early Trials tamoxifen + CB-228 Sensitive : C3
NFE2L2 E79K	Lung Non-Small Cell Squamous Cancer	NFE2L2 E79K	Lung Non-Small Cell Squamous Cancer	CB-228 Sensitive: C3 – Early Trials CB-228 Sensitive : C3	CB-228 Sensitive: C3 – Early Trials CB-228 Sensitive : C3
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	CB-228 Sensitive: C3 – Early Trials CB-228 Sensitive : C3	CB-228 Sensitive: C3 – Early Trials CB-228 Sensitive : C3
AKT1 mutation + HR positive	HER2 Negative Breast Cancer	AKT1 mutation + HR positive	HER2 Negative Breast Cancer	CB-228 Sensitive: C3 – Early Trials CB-228 Sensitive : C3	CB-228 Sensitive: C3 – Early Trials CB-228 Sensitive : C3
EWSR1-POU5F1 fusion	Renal Cell Carcinoma	EWSR1-POU5F1 fusion	Renal Cell Carcinoma	CB-228 Sensitive: C3 – Early Trials CB-228 Sensitive : C3	CB-228 Sensitive: C3 – Early Trials CB-228 Sensitive : C3
AKT1 mutation + mTOR mutation	Leiomyosarcoma	AKT1 mutation + mTOR mutation	Leiomyosarcoma	CB-228 Sensitive: C3 – Early Trials CB-228 Sensitive : C3	CB-228 Sensitive: C3 – Early Trials CB-228 Sensitive : C3
PTEN deletion	Renal Cell Carcinoma	PTEN deletion	Renal Cell Carcinoma	CB-228 Resistant: C3 – Early Trials CB-228 Resistant : C3	CB-228 Resistant: C3 – Early Trials CB-228 Resistant : C3
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	osimertinib + CB-228 Sensitive: C3 – Early Trials osimertinib + CB-228 Sensitive : C3	osimertinib + CB-228 Sensitive: C3 – Early Trials osimertinib + CB-228 Sensitive : C3